Farther Finance Advisors LLC Sells 1,833 Shares of Cencora, Inc. $COR

Farther Finance Advisors LLC reduced its stake in shares of Cencora, Inc. (NYSE:COR) by 40.6% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 2,679 shares of the company’s stock after selling 1,833 shares during the period. Farther Finance Advisors LLC’s holdings in Cencora were worth $837,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of COR. Parcion Private Wealth LLC grew its stake in Cencora by 4.1% during the third quarter. Parcion Private Wealth LLC now owns 1,872 shares of the company’s stock worth $585,000 after buying an additional 73 shares in the last quarter. Security Financial Services INC. raised its position in shares of Cencora by 2.6% in the 3rd quarter. Security Financial Services INC. now owns 1,325 shares of the company’s stock valued at $414,000 after buying an additional 33 shares in the last quarter. HBK Sorce Advisory LLC lifted its holdings in shares of Cencora by 9.5% during the 3rd quarter. HBK Sorce Advisory LLC now owns 15,881 shares of the company’s stock worth $4,933,000 after acquiring an additional 1,376 shares during the period. OFI Invest Asset Management boosted its position in shares of Cencora by 16.9% during the 3rd quarter. OFI Invest Asset Management now owns 436 shares of the company’s stock worth $136,000 after acquiring an additional 63 shares in the last quarter. Finally, Exchange Traded Concepts LLC boosted its position in shares of Cencora by 312.7% during the 3rd quarter. Exchange Traded Concepts LLC now owns 10,458 shares of the company’s stock worth $3,268,000 after acquiring an additional 7,924 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Buying and Selling at Cencora

In other news, EVP Elizabeth S. Campbell sold 3,351 shares of the firm’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the completion of the transaction, the executive vice president owned 23,891 shares of the company’s stock, valued at approximately $8,173,111.10. This trade represents a 12.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction on Monday, October 20th. The stock was sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the completion of the sale, the chief executive officer directly owned 37,940 shares in the company, valued at approximately $12,398,792. This represents a 11.84% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 20,317 shares of company stock worth $7,009,260. 10.80% of the stock is currently owned by company insiders.

Cencora Price Performance

Shares of COR opened at $340.08 on Tuesday. The company has a quick ratio of 0.55, a current ratio of 0.90 and a debt-to-equity ratio of 4.32. The stock has a market cap of $65.97 billion, a PE ratio of 42.78, a PEG ratio of 1.62 and a beta of 0.63. Cencora, Inc. has a 12-month low of $223.92 and a 12-month high of $377.54. The business has a 50-day simple moving average of $348.91 and a two-hundred day simple moving average of $315.59.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The firm had revenue of $83.73 billion for the quarter, compared to analyst estimates of $83.36 billion. During the same period last year, the firm posted $3.34 earnings per share. The business’s revenue for the quarter was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend was Friday, November 14th. This is a positive change from Cencora’s previous quarterly dividend of $0.55. Cencora’s payout ratio is presently 30.19%.

Analysts Set New Price Targets

Several equities research analysts have weighed in on COR shares. TD Cowen upped their target price on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Evercore ISI set a $400.00 price target on Cencora and gave the stock an “outperform” rating in a report on Thursday, November 6th. Mizuho upped their price objective on Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Wall Street Zen cut Cencora from a “buy” rating to a “hold” rating in a research report on Friday, November 28th. Finally, Wells Fargo & Company boosted their target price on Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, Cencora presently has an average rating of “Moderate Buy” and an average target price of $373.25.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.